金吾财讯 |据阿斯利康中国(AZN)消息，中国国家药品监督管理局已正式批准舒立瑞®（英文商品名： Soliris®，通用名：依库珠单抗注射液），适应症扩展至用于治疗6岁及以上抗乙酰胆碱受体（AChR）抗体阳性的难治性全身型重症肌无力（gMG）儿童患者。gMG是一种罕见的、致残性、慢性自身免疫性神经肌肉疾病，可导致肌肉功能丧失和严重衰弱。
金吾财讯 |据阿斯利康中国(AZN)消息，中国国家药品监督管理局已正式批准舒立瑞®（英文商品名： Soliris®，通用名：依库珠单抗注射液），适应症扩展至用于治疗6岁及以上抗乙酰胆碱受体（AChR）抗体阳性的难治性全身型重症肌无力（gMG）儿童患者。gMG是一种罕见的、致残性、慢性自身免疫性神经肌肉疾病，可导致肌肉功能丧失和严重衰弱。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.